Enterprise Value
120.7M
Cash
256.7M
Avg Qtr Burn
-27.68M
Short % of Float
18.77%
Insider Ownership
0.96%
Institutional Own.
73.70%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INPEFA™ (SOTAGLIFLOZIN) Details Heart disease, Heart failure | Approved Quarterly sales | |
XERMELO® (telotristat ethyl) Details Carcinoid syndrome diarrhea | Approved Quarterly sales | |
Sotagliflozin (Zynquista) (SGLT1/SGLT2) Details Type 1 diabetes, Diabetes | NDA Submission | |
LX9211 Details Neuropathy, Diabetic peripheral neuropathy | Phase 2b Initiation |